| ◆26th | Support for drug discovery seeds research at the University of Tokyo ~Activities of Drug Discovery Initiative ~ Hirotatsu Kojima, Ph.D. (Deputy Director, Drug Discovery Initiative, Graduate School of Pharmaceutical Sciences The University of Tokyo) |
| ◆25th | Biotech Engineering Company, Striving for Value Creation - For Comprehensive Healthcare System for Children as well as Families, and Society - Shinya Kurebayashi (Corporate Officer, CBO, Business Development Div. Kidswell Bio Corporation) |
| ◆24th | Future Challenges of Drug Discovery Research against Antimicrobial Resistance (AMR) Akihiko Fujie (Secretariat, AMED Public and Private Partnerships for Infectious Diseases R&D) |
| ◆23rd | Initiatives of Drug Discovery Research and Human Resource Development at Research Center for Drug Discovery, Faculty of Pharmacy, Keio University Yun-Gi Kim (Professor, Research Center for Drug Discovery, Faculty of Pharmacy, Keio University) |
| ◆22nd | Accelerating Drug Discovery Process with Genome Editing Technology from Tokushima Shinichiro Takezawa (CEO, Setsuro Tech Inc.) |
| ◆21st | Japan Society of Quality Assurance and Academia Yoshinobu Hirayama (President, Japan Society of Quality Assurance) |
| ◆20th | Introduction of AMED/BINDS Cryo-electron Microscopy Facility at the University of Tokyo Masahide Kikkawa, M.D., Ph.D. (Professor, Graduate School of Medicine, The University of Tokyo) |
| ◆19th | Introduction of Biologics Manufacturing Support Unit (BMS) Hitoshi Sakashita, Ph.D. (Manager, Manufacturing Technology Association of Biologics) |
| ◆18th | Patient empowerment as a new trend in drug development: beyond the goal of ISPACOS Tatsuro Irimura, Ph.D. (Project Professor, Division of Glycobiologics, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University) |
| ◆17th | Axcelead as a unique drug discovery solution provider Yoshinori Ikeura, Ph.D. (Chief Executive Officer, Axcelead Drug Discovery Partners, Inc.) |
| ◆16th | Support of Clinical Application for Breakthrough Seeds from Academia Frumitaka Nagamura (Professor, Director, Center for Translational Research, Institute of Medical Science, The University of Tokyo) |
| ◆15th | In supporting studies of drug seeds from academia Hiroshi Sumichika, Ph.D. (Drug Development Service Segment, Advanced Medical Business Development Department, LSI Medience Corporation) |
| ◆14th | Practical Application of Research Results by Drug Discovery and Development Carve-out Tohru Yoshikawa (Director & Secretary General, Bio New Combinations Research Institute) |
| ◆13th | Discovery of new drug discovery targets for African trypanosomiasis (African sleeping sickness)- Trypanosoma-Specific Allosteric Regulation Mechanisms by GMP Reductase - Takashi Inui (Professor, Graduate School of Life and Environmental Sciences, Osaka Prefecture University) |
| ◆12th | Comming Soon |
| ◆11th | Efforts to Standardize Real World Data Satomi Nagashima (Project Researcher, Department of Healthcare Information Management, University of Tokyo Hospital) |
| ◆10th | Accelerating Commercialization of Drug Discovery Seeds through Sharing of Research and Business Roles Takashi Nakaoka (Manager, Beyond Next Ventures, Inc.) |
| ◆9th | Development of an in vitro assay to evaluate higher brain functions for drug discovery Noriko Koganezawa and Tomoaki Shirao (Department of Neurobiology and Behavior, Gunma University Graduate School of Medicine) |
| ◆8th | Participation in DISC Business with Miniaturized HTS as a Bridge Kenji Wakabayashi, Ph.D. (Vice President, Biological Research Department, Daiichi Sankyo RD Novare Co., LTD.) |
| ◆7th | Cell Therapy and Drug Discovery Research based on Next-Generation Gene Transfer Technology / Artificial Chromosome Vectors Yasuhiro Kazuki, Ph.D. (Associate Professor, Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Chromosome Engineering Research Center (CERC) Director, Tottori Pharmaceutical Innovation Center (TPIC) ) |
| ◆6th | Challenges to "Reverse Value Generation" Drug Discovery Hiroshi Nagabukuro, Ph.D. (COO/CSO, ARTham Therapeutic/ Adjunct Professor, Oita University, Faculty of Medicine, Department of Clinical Pharmacology & Therapeutics) |
| ◆5th | Small Biotech with a Big Vision Masaaki Sawa, Ph.D. (Chief Scientific Officer, CARNA BIOSCIENCES, INC.) |
| ◆4th | Development of Nasal Drug Delivery System = Translational Research Business Shuichi Kanazashi, Ph.D. (President, Shin Nippon Biomedical Laboratories, Ltd.) |
| ◆3rd | SEND, FDA, and Industry Movement Takayuki Anzai (Professor (AP), Showa University, School of Medicine) |
| ◆2nd | Drug Discovery in Academia – Initiatives by NIBIOHN Yoshihiro Yoneda (Director General, National Institutes of Biomedical Innovation, Health and Nutrition) |
| ◆1st | Aspiring to be a Navigator of Innovative Drug Discovery Development Noriatsu Kono (Managing Director, Department of Innovative Drug Discovery and Development, Japan Agency for Medical Research and Development) |
The column was written based on the lecture given at the "TRS Academia Consortium Symposium" held in February 2024.
| ◆ | Towards Practical Application of Research in Academia Tetsuya Kurihara (Partner, Shinsei Capital Partners Ltd.※) ※ Affiliation at the time of the presentation, February 2024. |
| ◆ | Background to the Establishment of the First Startup from Kitasato University Faculty of Pharmacy - The Utilization and Importance of Incubation Support -NEW Kanji Hosoda (President and CEO, PRD Therapeutics, Inc.) |
| ◆ | Four Years as a New CEO of a Drug Discovery Venture Tomoaki Shirao, M.D., PhD. (President and CEO/ AlzMed, Inc.) |
| ◆3rd | Innovative Cancer Screening Test Uses the Olfactory Sensory Function of Nematodes "Unrelenting Challenges against Cancer with Nematodes (C. elegans)" Takaaki Hirotsu, Ph.D. (President & CEO, Hirotsu Bio Science Inc.) |
| ◆2nd | Dynamism in Brain Science and Functional Brain Imaging “Be a Researcher Making Own Wheel” Ryuta Kawashima (Director and professor, the Institute of Development, Aging and Cancer, Tohoku University/ Director and CTO (Chief Technical Officer), NeU Corporation) |
| ◆1st | Current Vaccine Drug Discovery and What We Need to Consider Now Ken Ishii (Professor, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo) |
